Parabilis Medicines, Inc. Common Stock (PBLS) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · United States · ISIN US6989551014

Price
26.92 USD
Market cap
3.33 bn USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
882.89 %
Return on assets (ROA)
-180.51 %

Parabilis Medicines, Inc. Common Stock financials

Fiscal year20242025
Revenue0.00 USD0.00 USD
Operating income-126.13 m USD-152.08 m USD
EBIT-116.43 m USD-144.37 m USD
Net income-117.91 m USD-145.89 m USD
Diluted EPS – continuing operations-60.96 USD-72.11 USD

Full history since 2024, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Parabilis Medicines, Inc. Common Stock

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.